 determin growth fraction advanc prostat cancer immunostain relationship time progress hormon therapi reliabl predictor respons prostat cancer patient undergo hormon therapi studi possibl tumor prolifer rate tumor behavior patient growth fraction metastat prostat cancer biopsi specimen androgen withdraw therapi antibodi immunohistochem studi tumor growth fraction time progress therapi percentag malign epitheli nuclei primari tumor patient median patient respons group median time progress poor respond time progress month good respond equal month similar growth fraction versu nuclei patient group median growth fraction patient high growth fraction nuclei time progress median month patient low growth fraction median time progress month statist signific interest trend immunostain accur time progress individu patient undergo hormon therapi reliabl predict growth rate measur cell prolifer cell death rate